Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

about

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

Item

http://www.wikidata.org/entity/Q55138800

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

@en

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

@nl

type

Item

label

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

@en

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

@nl

prefLabel

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

@en

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

@nl

P1476

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.

@en

P2093

Julia Morawski

http://www.w3.org/2001/XMLSchema#string

Karthinathan Thangavelu

http://www.w3.org/2001/XMLSchema#string

Mark S Freedman

http://www.w3.org/2001/XMLSchema#string

P2860

Teriflunomide for multiple sclerosis

Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.

World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.

P304

2055217318775236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2055217318775236

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29796289

http://www.w3.org/2001/XMLSchema#string

P932

5960864

http://www.w3.org/2001/XMLSchema#string